Skip to main content
. 2012 Jun 28;2012:1007.
Ref (type) Population Outcome, Interventions Results and statistical analysis Effect size Favours
Adverse effects

Systematic review		 3670 people
12 RCTs in this analysis		 Extrapyramidal symptoms
with haloperidol
with olanzapine
Absolute results not reported
RR 0.39
95% CI 0.30 to 0.51 		Moderate effect size olanzapine

Systematic review		 2952 people
9 RCTs in this analysis		 Mean difference in weight gain (kg)
with haloperidol
with olanzapine
Absolute results not reported
Mean difference 3.3 kg
95% CI 2.2 kg to 4.4 kg 		Effect size not calculated haloperidol

Systematic review		 2762 people
6 RCTs in this analysis		 Sedation
with haloperidol
with olanzapine
Absolute results not reported
RR 0.95
95% CI 0.82 to 1.10 		Not significant

Systematic review		 83 people
Data from 1 RCT		 Difference in percentage of patients withdrawing because of adverse events short term
with haloperidol (mean modal dose 10.8 mg/day)
with olanzapine (mean modal dose 11.6 mg/day)
Absolute results not reported
Difference 15%
P value not reported

Systematic review		 83 people
Data from 1 RCT		 Extrapyramidal symptoms, mean change from baseline to endpoint in Simpson-Angus Scale (SAS) total score short term
+4.5 with haloperidol (mean modal dose 10.8 mg/day)
–0.5 with olanzapine (mean modal dose 11.6 mg/day)
P <0.001 		Effect size not calculated olanzapine

Systematic review		 83 people
Data from 1 RCT		 Akathisia, mean change from baseline to endpoint on Barnes Akathisia Scale (BAS) short term
+0.5 with haloperidol (mean modal dose 10.8 mg/day)
–0.1 with olanzapine (mean modal dose 11.6 mg/day)
P = 0.005 		Effect size not calculated olanzapine

Systematic review		 83 people
Data from 1 RCT		 Difference in percentage of people receiving anticholinergic medications short term
with haloperidol (mean modal dose 10.8 mg/day)
with olanzapine (mean modal dose 11.6 mg/day)
Absolute results not reported
Difference 28.1%
P = 0.008 		Effect size not calculated olanzapine

Systematic review		 83 people
Data from 1 RCT		 Mean increase in body weight (kg) short term
0.5 kg with haloperidol (mean modal dose 10.8 mg/day)
4.1 kg with olanzapine (mean modal dose 11.6 mg/day)
P <0.001 		Effect size not calculated haloperidol

Systematic review		 83 people
Data from 1 RCT		 Prolactin at endpoint short term
with haloperidol (mean modal dose 10.8 mg/day)
with olanzapine (mean modal dose 11.6 mg/day)
Absolute results not reported
4.5 times higher in haloperidol group
P <0.001 		Effect size not calculated olanzapine

Systematic review		 263 people
Data from 1 RCT		 Difference in percentage of people withdrawing because of adverse events
7% with haloperidol (mean modal dose 4.4 mg/day)
3% with olanzapine (mean modal dose 9.1 mg/day)
Absolute numbers not reported
P value not reported

Systematic review		 263 people
Data from 1 RCT		 Difference in incidence of treatment-emergent parkinsonism short term
54.8% with haloperidol (mean modal dose 4.4 mg/day)
26.1% with olanzapine (mean modal dose 9.1 mg/day)
Absolute numbers not reported
P <0.001 		Effect size not calculated olanzapine

Systematic review		 263 people
Data from 1 RCT		 Difference in incidence of treatment-emergent akathisia short term
51.2% with haloperidol (mean modal dose 4.4 mg/day)
11.9% with olanzapine (mean modal dose 9.1 mg/day)
Absolute numbers not reported
P <0.001 		Effect size not calculated olanzapine

Systematic review		 263 people
Data from 1 RCT		 Mean increase in prolactin short term
6.9 ng/mL with haloperidol (mean modal dose 4.4 mg/day)
1.2 ng/mL with olanzapine (mean modal dose 9.1 mg/day)
P <0.0001 		Effect size not calculated olanzapine

Systematic review		 263 people
Data from 1 RCT		 Proportion of people with a >7% increase in body weight short term
23% with haloperidol (mean modal dose 4.4 mg/day)
62% with olanzapine (mean modal dose 9.1 mg/day)
Absolute numbers not reported
P <0.001 		Effect size not calculated haloperidol

Systematic review		 263 people
Data from 1 RCT		 Percentage of people withdrawing because of adverse events long term
16% with haloperidol (mean modal dose 4.4 mg/day)
7% with olanzapine (mean modal dose 9.1 mg/day)
Absolute numbers not reported
P <0.03 		Effect size not calculated olanzapine

Systematic review		 263 people
Data from 1 RCT		 Symptoms of parkinsonism (SAS) long term
4.57 with haloperidol (mean modal dose 4.4 mg/day)
2.28 with olanzapine (mean modal dose 9.1 mg/day)
P <0.001 		Effect size not calculated olanzapine

Systematic review		 263 people
Data from 1 RCT		 Symptoms of akathisia (BAS) long term
2.83 with haloperidol (mean modal dose 4.4 mg/day)
0.98 with olanzapine (mean modal dose 9.1 mg/day)
P <0.0001 		Effect size not calculated olanzapine

Systematic review		 263 people
Data from 1 RCT		 Percentage of people receiving anticholinergic medications long term
47% with haloperidol (mean modal dose 4.4 mg/day)
20% with olanzapine (mean modal dose 9.1 mg/day)
Absolute results not reported
P <0.0001 		Effect size not calculated olanzapine

Systematic review		 263 people
Data from 1 RCT		 Percentage of people with a >7% increase in weight gain long term
42% with haloperidol (mean modal dose 4.4 mg/day)
72% with olanzapine (mean modal dose 9.1 mg/day)
Absolute numbers not reported
P <0.0001 		Effect size not calculated olanzapine

Systematic review		 263 people
Data from 1 RCT		 Percentage of people with at least one abnormal prolactin level
67% with haloperidol (mean modal dose 4.4 mg/day)
50% with olanzapine (mean modal dose 9.1 mg/day)
Absolute numbers not reported
P <0.0004 		Effect size not calculated olanzapine

RCT		 27 people Difference in mean Extrapyramidal Symptom Rating Scale (ESRS) parkinsonism days 0 to 56
5.69 to 6.80 with haloperidol (average daily dose 9.32 mg)
6.93 to 7.79 with olanzapine (average daily dose 12 mg)
P >0.05 		Not significant

RCT		 35 people Extrapyramidal symptoms, change from baseline in SAS total score endpoint
0.95 to 0.89 with haloperidol (doses 15–20 mg/day)
1.63 to 1.00 with olanzapine (doses 15–20 mg/day)
P = 0.523 		Not significant

RCT		 35 people Extrapyramidal symptoms, change from baseline in Abnormal Involuntary Movement Scale (AIMS) total score endpoint
0.74 to 0.53 with haloperidol (doses 15–20 mg/day)
1.63 to 1.00 with olanzapine (doses 15–20 mg/day)
P = 0.894 		Not significant

RCT		 35 people Change from baseline in weight (lb) endpoint
197.05 lb to 194.08 lb with haloperidol (doses 15–20 mg/day)
194.91 lb to 203.28 lb with olanzapine (doses 15–20 mg/day)
P = 0.012 		Effect size not calculated haloperidol

RCT		 35 people Change from baseline in glucose (mg/dL) endpoint
84.44 mg/dL to 83.22 mg/dL with haloperidol (doses 15–20 mg/day)
100.73 mg/dL to 94.00 mg/dL with olanzapine (doses 15–20 mg/day)
P = 0.031 		Effect size not calculated olanzapine

RCT		 276 people Any adverse effect
58% with haloperidol (doses 5–20 mg/day)
42% with olanzapine (doses 5–20 mg/day)
Absolute numbers not reported
P = 0.011 		Effect size not calculated olanzapine

RCT		 276 people Akathisia, change from baseline in BAS total score 8 weeks
+0.7 with haloperidol (doses 5–20 mg/day)
–0.2 with olanzapine (doses 5–20 mg/day)
P = 0.001 		Effect size not calculated olanzapine

RCT		 276 people Akathisia, change from baseline in BAS total score 24 weeks
+0.5 with haloperidol (doses 5–20 mg/day)
–0.2 with olanzapine (doses 5–20 mg/day)
P = 0.003 		Effect size not calculated olanzapine

RCT		 276 people Extrapyramidal symptoms, change from baseline in SAS total score 8 weeks
+1.0 with haloperidol (doses 5–20 mg/day)
–0.9 with olanzapine (doses 5–20 mg/day)
P <0.001 		Effect size not calculated olanzapine

RCT		 276 people Extrapyramidal symptoms, change from baseline in SAS total score 24 weeks
+0.4 with haloperidol (doses 5–20 mg/day)
–1.0 with olanzapine (doses 5–20 mg/day)
P <0.001 		Effect size not calculated olanzapine

RCT		 276 people Extrapyramidal symptoms: change from baseline in AIMS total score 8 weeks
–0.1 with haloperidol (doses 5–20 mg/day)
–0.8 with olanzapine (doses 5–20 mg/day)
P = 0.053 		Not significant

RCT		 276 people Extrapyramidal symptoms: change from baseline in AIMS total score 24 weeks
–0.3 with haloperidol (doses 5–20 mg/day)
–0.9 with olanzapine (doses 5–20 mg/day)
P = 0.096 		Not significant

RCT		 276 people Weight gain (in excess of 7% of baseline weight)
12% with haloperidol (doses 5–20 mg/day)
26% with olanzapine (doses 5–20 mg/day)
Absolute numbers not reported
P = 0.012 		Effect size not calculated haloperidol

RCT		 276 people Dystonia
5% with haloperidol (doses 5–20 mg/day)
0% with olanzapine (doses 5–20 mg/day)
Absolute numbers not reported
P = 0.01 		Effect size not calculated olanzapine

RCT		 276 people Tremor
14% with haloperidol (doses 5–20 mg/day)
6% with olanzapine (doses 5–20 mg/day)
Absolute numbers not reported
P = 0.014 		Effect size not calculated olanzapine